Aridis Pharmaceuticals (ARDS) News Today $0.0017 +0.00 (+750.00%) As of 05/22/2026 03:52 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ARDS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Aridis Pharmaceuticals, Inc. (ARDS) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comAridis Provides Corporate UpdateDecember 20, 2024 | globenewswire.comHorizon Tech Finance (NASDAQ:HRZN) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comGenor Biopharma Holdings Limited (67N0.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comBreathing easier: Nature-inspired treatments could relieve acute respiratory distressAugust 3, 2024 | msn.comAridis Provides Corporate UpdateJune 24, 2024 | globenewswire.comAridis Pharmaceuticals Inc (ARDS)March 14, 2024 | uk.investing.comIrish Cup: Institute's quarter-final place confirmed as IFA rejects Ards protestFebruary 10, 2024 | bbc.co.ukAridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024December 15, 2023 | finance.yahoo.comAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNovember 3, 2023 | markets.businessinsider.comAridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNovember 3, 2023 | finance.yahoo.comAridis Pharmaceuticals Inc ARDSNovember 1, 2023 | morningstar.comMAridis Pharmaceuticals Stock (OTC:ARDS), Analyst Ratings, Price Targets, PredictionsOctober 22, 2023 | benzinga.comHC Wainwright & Co. Maintains Aridis Pharmaceuticals (ARDS) Buy RecommendationOctober 21, 2023 | msn.comFDA’s Qualified Infectious Disease Product Designation Bolsters Aridis Pharmaceuticals’ Investment Appeal: An Analyst’s Buy RecommendationOctober 20, 2023 | markets.businessinsider.comARDS Sep 2023 2.500 callSeptember 15, 2023 | finance.yahoo.comAridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TVSeptember 15, 2023 | finance.yahoo.comAridis Pharma (ARDS) Earnings Dates & ReportsAugust 21, 2023 | investing.comAridis Pharmaceuticals Announces $2 Million OfferingAugust 2, 2023 | finance.yahoo.comWhy Are Aridis Pharmaceuticals Shares Moving Higher Today?July 18, 2023 | finance.yahoo.comAridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301July 17, 2023 | finance.yahoo.comAridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301July 13, 2023 | finance.yahoo.comAridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) DesignationJuly 12, 2023 | finance.yahoo.comAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)June 22, 2023 | marketwatch.comAridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)June 20, 2023 | finance.yahoo.comAridis Pharmaceuticals, Inc.: Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateJune 9, 2023 | finanznachrichten.deAridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateJune 8, 2023 | finance.yahoo.comAridis Pharmaceuticals Stock (NASDAQ:ARDS), Guidance and ForecastJune 1, 2023 | benzinga.comAridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study DesignMay 31, 2023 | finance.yahoo.comAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-QMay 25, 2023 | finance.yahoo.comAridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-KApril 26, 2023 | finance.yahoo.comBig pharma, small drug maker spar over pneumonia drug dealApril 3, 2023 | bizjournals.comAridis Provides Corporate UpdateMarch 31, 2023 | finance.yahoo.comAstraZeneca Axes Pneumonia Drug Pact With AridisMarch 29, 2023 | msn.comWhy Aridis Pharmaceuticals Shares Are DivingMarch 14, 2023 | msn.comAridis Pharmaceuticals Shares Tumble After Stock Offering >ARDSMarch 14, 2023 | marketwatch.comAridis (ARDS) Stock Up as Cystic Fibrosis Study Meets GoalsMarch 14, 2023 | msn.comAridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common StockMarch 14, 2023 | finance.yahoo.comAridis Skyrockets on Impressive Data In Cystic FibrosisMarch 13, 2023 | msn.comAridis stock surges ~35% as lung disease drug AR-501 meets main goal in mid-stage studyMarch 13, 2023 | msn.comWhy Aridis Pharmaceuticals Shares Are Soaring TodayMarch 13, 2023 | finance.yahoo.comAridis Shares Rally Premarket on Positive Phase 2a Cystic Fibrosis Study >ARDSMarch 13, 2023 | marketwatch.comAridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis PatientsMarch 13, 2023 | finance.yahoo.comInterviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money ReportFebruary 17, 2023 | finanznachrichten.deWhen Will Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Breakeven?February 15, 2023 | finance.yahoo.comIn virtuous cycle, foundation uses drug royalty riches to back new cystic fibrosis drug research in Bay AreaFebruary 6, 2023 | finance.yahoo.comHere's Why Aridis Pharmaceuticals (ARDS) Is a Great 'Buy the Bottom' Stock NowFebruary 1, 2023 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Aridis Pharmaceuticals (ARDS) and Acurx Pharmaceuticals (ACXP)January 27, 2023 | markets.businessinsider.comAridis stock slumps ~25% as antibody drug fails phase 3 trial in pneumoniaJanuary 26, 2023 | msn.comAridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)January 25, 2023 | finance.yahoo.com Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARDS Media Mentions By Week ARDS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARDS News Sentiment▼0.000.44▲Average Medical News Sentiment ARDS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARDS Articles This Week▼00▲ARDS Articles Average Week Get the Latest News and Ratings for ARDS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aridis Pharmaceuticals and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ONCO News LIPO News ADTX News CARM News AIMDW News RNA News CELUW News ENGNW News FBIOP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARDS) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYou have until June 1Macroeconomic strategist Dr. Mark Skousen believes June 1 marks a critical turning point for one of the most o...The Oxford Club | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
